Biotage AB (BIOT) - Net Assets

Latest as of March 2025: Skr3.85 Billion SEK ≈ $413.89 Million USD

Based on the latest financial reports, Biotage AB (BIOT) has net assets worth Skr3.85 Billion SEK (≈ $413.89 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr4.71 Billion ≈ $506.66 Million USD) and total liabilities (Skr862.00 Million ≈ $92.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BIOT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr3.85 Billion
% of Total Assets 81.69%
Annual Growth Rate 6.52%
5-Year Change 315.44%
10-Year Change 652.39%
Growth Volatility 30.79

Biotage AB - Net Assets Trend (2000–2024)

This chart illustrates how Biotage AB's net assets have evolved over time, based on quarterly financial data. Also explore BIOT asset base for the complete picture of this company's asset base.

Annual Net Assets for Biotage AB (2000–2024)

The table below shows the annual net assets of Biotage AB from 2000 to 2024. For live valuation and market cap data, see Biotage AB stock valuation.

Year Net Assets Change
2024-12-31 Skr4.11 Billion
≈ $442.62 Million		 +12.47%
2023-12-31 Skr3.66 Billion
≈ $393.55 Million		 +123.40%
2022-12-31 Skr1.64 Billion
≈ $176.17 Million		 +19.31%
2021-12-31 Skr1.37 Billion
≈ $147.65 Million		 +38.58%
2020-12-31 Skr990.04 Million
≈ $106.54 Million		 +13.08%
2019-12-31 Skr875.50 Million
≈ $94.22 Million		 +24.68%
2018-12-31 Skr702.18 Million
≈ $75.57 Million		 +15.37%
2017-12-31 Skr608.61 Million
≈ $65.50 Million		 +8.06%
2016-12-31 Skr563.24 Million
≈ $60.61 Million		 +3.03%
2015-12-31 Skr546.66 Million
≈ $58.83 Million		 +8.75%
2014-12-31 Skr502.65 Million
≈ $54.09 Million		 +5.43%
2013-12-31 Skr476.77 Million
≈ $51.31 Million		 -10.18%
2012-12-31 Skr530.83 Million
≈ $57.13 Million		 -5.86%
2011-12-31 Skr563.90 Million
≈ $60.68 Million		 -0.71%
2010-12-31 Skr567.95 Million
≈ $61.12 Million		 -47.85%
2009-12-31 Skr1.09 Billion
≈ $117.20 Million		 -3.18%
2008-12-31 Skr1.12 Billion
≈ $121.05 Million		 +41.26%
2007-12-31 Skr796.26 Million
≈ $85.69 Million		 +11.76%
2006-12-31 Skr712.47 Million
≈ $76.67 Million		 -3.49%
2005-12-31 Skr738.25 Million
≈ $79.45 Million		 +41.12%
2004-12-31 Skr523.13 Million
≈ $56.30 Million		 -14.17%
2003-12-31 Skr609.50 Million
≈ $65.59 Million		 -1.08%
2002-12-31 Skr616.16 Million
≈ $66.31 Million		 -21.51%
2001-12-31 Skr784.98 Million
≈ $84.48 Million		 -13.01%
2000-12-31 Skr902.36 Million
≈ $97.11 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Biotage AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 153700000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings Skr1.54 Billion 37.37%
Common Stock Skr113.00 Million 2.75%
Other Components Skr2.46 Billion 59.88%
Total Equity Skr4.11 Billion 100.00%

Biotage AB Competitors by Market Cap

The table below lists competitors of Biotage AB ranked by their market capitalization.

Company Market Cap
Treehouse Foods Inc
NYSE:THS
 $1.23 Billion
Suzhou Chunqiu Electronic Technology Co Ltd Class A
SHG:603890
 $1.23 Billion
INKON Life Technology Co Ltd
SHE:300143
 $1.23 Billion
Under Armour Inc C
NYSE:UA
 $1.23 Billion
Henan Yicheng New Energy Co Ltd
SHE:300080
 $1.23 Billion
GMP Property SOCIMI SA
MC:YGMP
 $1.23 Billion
Tourmaline Bio Inc.
NASDAQ:TRML
 $1.23 Billion
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
 $1.23 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Biotage AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 3,657,000,000 to 4,113,000,000, a change of 456,000,000 (12.5%).
  • Net income of 284,000,000 contributed positively to equity growth.
  • Dividend payments of 128,000,000 reduced retained earnings.
  • Share repurchases of 2,000,000 reduced equity.
  • New share issuances of 2,000,000 increased equity.
  • Other comprehensive income increased equity by 124,000,000.
  • Other factors increased equity by 176,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr284.00 Million +6.9%
Dividends Paid Skr128.00 Million -3.11%
Share Repurchases Skr2.00 Million -0.05%
Share Issuances Skr2.00 Million +0.05%
Other Comprehensive Income Skr124.00 Million +3.01%
Other Changes Skr176.00 Million +4.28%
Total Change Skr- 12.47%

Book Value vs Market Value Analysis

This analysis compares Biotage AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.79x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 13.43x to 2.79x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 Skr10.66 Skr143.20 x
2003-12-31 Skr10.55 Skr143.20 x
2004-12-31 Skr8.96 Skr143.20 x
2005-12-31 Skr10.46 Skr143.20 x
2006-12-31 Skr8.02 Skr143.20 x
2007-12-31 Skr8.95 Skr143.20 x
2008-12-31 Skr12.71 Skr143.20 x
2009-12-31 Skr12.34 Skr143.20 x
2010-12-31 Skr6.80 Skr143.20 x
2011-12-31 Skr7.22 Skr143.20 x
2012-12-31 Skr7.25 Skr143.20 x
2013-12-31 Skr7.00 Skr143.20 x
2014-12-31 Skr7.77 Skr143.20 x
2015-12-31 Skr8.45 Skr143.20 x
2016-12-31 Skr8.70 Skr143.20 x
2017-12-31 Skr9.40 Skr143.20 x
2018-12-31 Skr10.85 Skr143.20 x
2019-12-31 Skr13.43 Skr143.20 x
2020-12-31 Skr15.18 Skr143.20 x
2021-12-31 Skr20.96 Skr143.20 x
2022-12-31 Skr24.73 Skr143.20 x
2023-12-31 Skr49.42 Skr143.20 x
2024-12-31 Skr51.35 Skr143.20 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Biotage AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 6.90%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 13.81%
  • • Asset Turnover: 0.40x
  • • Equity Multiplier: 1.24x
  • Recent ROE (6.90%) is above the historical average (2.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -27.33% -172.55% 0.14x 1.10x Skr-229.99 Million
2003 -40.10% -140.74% 0.21x 1.36x Skr-305.35 Million
2004 -21.99% -31.37% 0.53x 1.33x Skr-167.33 Million
2005 -5.40% -9.27% 0.44x 1.32x Skr-113.72 Million
2006 0.40% 0.54% 0.57x 1.29x Skr-68.43 Million
2007 12.48% 20.02% 0.50x 1.24x Skr19.75 Million
2008 26.59% 77.62% 0.30x 1.15x Skr186.57 Million
2009 1.24% 3.42% 0.32x 1.13x Skr-95.42 Million
2010 -72.23% -95.64% 0.62x 1.22x Skr-467.04 Million
2011 5.76% 7.58% 0.61x 1.24x Skr-23.91 Million
2012 7.22% 8.28% 0.71x 1.23x Skr-14.75 Million
2013 8.68% 9.31% 0.75x 1.24x Skr-6.29 Million
2014 10.17% 10.42% 0.79x 1.23x Skr847.00K
2015 13.40% 12.00% 0.91x 1.22x Skr18.59 Million
2016 16.48% 13.89% 0.96x 1.23x Skr36.47 Million
2017 22.80% 18.55% 0.99x 1.24x Skr77.89 Million
2018 23.87% 18.40% 0.91x 1.43x Skr97.41 Million
2019 21.34% 16.96% 0.82x 1.53x Skr99.27 Million
2020 17.68% 16.02% 0.76x 1.45x Skr76.00 Million
2021 14.94% 16.64% 0.62x 1.45x Skr67.80 Million
2022 16.37% 17.11% 0.67x 1.43x Skr104.30 Million
2023 6.73% 13.21% 0.38x 1.35x Skr-119.70 Million
2024 6.90% 13.81% 0.40x 1.24x Skr-127.30 Million

Industry Comparison

This section compares Biotage AB's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $183,744,111
  • Average return on equity (ROE) among peers: -54.11%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Biotage AB (BIOT) Skr3.85 Billion -27.33% 0.22x $1.23 Billion
ADDvise Group AB A (ADDV-A) $3.30 Million 33.40% 2.57x $4.23 Million
ADDvise Group B (ADDV-B) $835.00 Million 10.78% 3.13x $108.58 Million
AddLife AB (publ) (ALIF-B) $346.60 Million 22.45% 2.68x $1.80 Billion
Bonesupport Holding AB (BONEX) $34.30 Million -321.22% 4.50x $1.56 Billion
Dynavox Group (DYVOX) $139.50 Million 21.36% 7.22x $930.88 Million
iZafe Group AB Series B (IZAFE-B) $40.73 Million -89.06% 0.19x $14.83 Million
Ortivus AB ser. A (ORTI-A) $22.41 Million -97.60% 2.16x $322.08K
Ortivus AB ser. B (ORTI-B) $224.47 Million 5.79% 0.15x $14.04 Million
S2Medical AB (S2M) $7.38 Million -72.91% 0.51x $611.88K

About Biotage AB

ST:BIOT Sweden Medical Instruments & Supplies
Market Cap
$1.23 Billion
Skr11.46 Billion SEK
Market Cap Rank
#8220 Global
#126 in Sweden
Share Price
Skr143.20
Change (1 day)
+0.14%
52-Week Range
Skr141.00 - Skr143.40
All Time High
Skr280.87
Categories
Companies in Sweden Medical Instruments & Supplies
About

Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation produ… Read more